{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "Treatment of adult and pediatric patients with refractory primary mediastinal large B-Cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy",
    "geneContextQualifier": "--",
    "objectTherapeutic": "Pembrolizumab [Keytruda]"
}